Focus: Maze Therapeutics is a clinical-stage biotech focused on small molecules, gene therapy, antisense oligonucleotides, and biologics, headquartered in South San Francisco. The company is advancing a pipeline in gene therapy and rare genetic diseases with three active clinical programs.
Profile data last refreshed 2h ago · AI intelligence enriched 3w ago
Stable — net +1 jobs in 30d
4 added, 3 removed. Backfill posture.
Maze is a lean, publicly-traded early-stage biotech best suited for operators comfortable with clinical execution risk and long timelines to value creation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Maze Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Maze Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
An officer plans a $476K share sale at Maze Therapeutics (MAZE). - Stock Titan
An officer plans a $476K share sale at Maze Therapeutics (MAZE). Stock Titan
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock - Yahoo Finance
What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock Yahoo Finance
Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential - Investing.com
Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential Investing.com
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39% - Yahoo Finance
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39% Yahoo Finance
Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History Yahoo! Finance Canada
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - Yahoo Finance UK
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history Yahoo Finance UK
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo